Go Pro
NASDAQ:MSLE

Satellos Bioscience Q1 2026 Earnings Report

$9.05 +0.39 (+4.52%)
As of 09:31 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Satellos Bioscience EPS Results

Actual EPS
-$0.53
Consensus EPS
-$0.51
Beat/Miss
Missed by -$0.02
One Year Ago EPS
N/A

Satellos Bioscience Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Satellos Bioscience Announcement Details

Quarter
Q1 2026
Time
Before Market Opens
Conference Call Date
Friday, May 15, 2026
Conference Call Time
7:00AM ET

Earnings Documents

Satellos Bioscience Earnings Headlines

Q3 EPS Estimate for Satellos Bioscience Reduced by Analyst
Satellos Bioscience Inc
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.tc pixel
See More Satellos Bioscience Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Satellos Bioscience? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Satellos Bioscience and other key companies, straight to your email.

About Satellos Bioscience

Satellos Bioscience (NASDAQ:MSLE) is a regenerative medicine company dedicated to developing novel therapeutics which stimulate or restore muscle regeneration in severe disorders. The company's lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy. Satellos Bioscience Inc., formerly known as iCo Therapeutics Inc., is based in Toronto, Ontario.

View Satellos Bioscience Profile